# Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

> **NCT06758947** · PHASE3 · COMPLETED · sponsor: **Assiut University** · enrollment: 60 (actual)

## Conditions studied

- Interstitial Lung Disease Due to Systemic Disease (Disorder)

## Interventions

- **DRUG:** Upadacitinib 15 MG
- **DEVICE:** Cellcept Oral Product

## Key facts

- **NCT ID:** NCT06758947
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-15
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06758947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06758947, "Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06758947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*